Profiel
Ren Xu currently works as a Chief Operating Officer at REMD Biotherapeutics, Inc.
Actieve functies van Ren Xu
Bedrijven | Functie | Begin |
---|---|---|
REMD Biotherapeutics, Inc.
REMD Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology REMD Biotherapeutics, Inc. is a clinical-stage biotechnology company that focuses on developing protein-based therapies to treat metabolic diseases and other serious illnesses. The private company was founded in 2011 by two former Amgen research scientists, Yan Hai and Tom Boone, and is based in Camarillo, CA, with additional facilities in Beijing. REMD Biotherapeutics has established several unique antibody research and development platforms, including a G protein-coupled receptors (GPCRs) antibody platform, a Synermab bispecific antibody platform, and a tumor-activating interferon (TAI) bifunctional antibody interferon fusion platform. The company's most advanced program is volagidemab (REMD-477), a fully human antibody that has completed phase 2 clinical studies in type 1 and type 2 diabetes and is in preparation for initiating multi-center clinical phase 3 studies in type 1 diabetes. | Operationeel Directeur | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 1 |
---|---|
REMD Biotherapeutics, Inc.
REMD Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology REMD Biotherapeutics, Inc. is a clinical-stage biotechnology company that focuses on developing protein-based therapies to treat metabolic diseases and other serious illnesses. The private company was founded in 2011 by two former Amgen research scientists, Yan Hai and Tom Boone, and is based in Camarillo, CA, with additional facilities in Beijing. REMD Biotherapeutics has established several unique antibody research and development platforms, including a G protein-coupled receptors (GPCRs) antibody platform, a Synermab bispecific antibody platform, and a tumor-activating interferon (TAI) bifunctional antibody interferon fusion platform. The company's most advanced program is volagidemab (REMD-477), a fully human antibody that has completed phase 2 clinical studies in type 1 and type 2 diabetes and is in preparation for initiating multi-center clinical phase 3 studies in type 1 diabetes. | Health Technology |